Tirzepatide
FDA ApprovedA dual GIP and GLP-1 receptor agonist. FDA approved for type 2 diabetes, with remarkable weight loss data showing up to 20% body weight reduction in trials.
Weight ManagementMetabolic HealthGLP-1 Agonist
Half Life
~5 days
Time to Results
4-12 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyOnce weekly
Cost$$$
🐾 Griffin Says...
Often called the upgraded semaglutide. The SURMOUNT trials showed 20.8% greater weight reduction than placebo. The dual receptor action appears to add meaningful extra benefit. One of the most exciting compounds in metabolic research right now.
Benefits
- Superior weight reduction vs semaglutide in trials
- Blood sugar control
- Appetite suppression
- Cardiovascular benefits
- Improved insulin sensitivity
Best For
- Weight management research
- Metabolic health
- Type 2 diabetes research
Body Systems
MetabolicCardiovascularEndocrine
Mechanisms of Action
- Dual GIP and GLP-1 receptor agonism
- Reduces appetite
- Slows gastric emptying
- Enhances insulin secretion
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Very Common | Mild-Moderate |
| Vomiting | Common | Mild |
| Diarrhea | Common | Mild |
Contraindications
History of thyroid cancer, pancreatitis, pregnancy
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator